Plavix Drug Eluting Stents - Clopidogrel 75mg

Switching directly to prasugrel from clopidogrel results in plavix drug eluting stents inhibition of platelet aggregation in aspirintreated subjects. What is the cutoff value for identifying patients who are low responders to clopidogrel plavix type of drug?

Subject with known active pathological bleeding or heightened risk of bleeding including but not limited to: gastrointestinal bleeding within 6 months, recent surgery or trauma. Inability of subject to provide informed consent. How to optimise clopidogrel therapy? Plavix drug eluting stents the lowresponse incidence by aggregometryguided therapy modification. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity.

In subjects with high residual levels of plavix drug eluting stents reactivity after receiving either a maintenance or loading dose of either clopidogrel or prasugrel, a cross over of thienopyridine treatment to the alternate medication will occur. Subject must be taking aspirin or enteric coated aspirin 81 mg325 mg daily. Willing to participate and sign an informed consent. Subject weight is 60 kg or plavix drug eluting stents. Subject with a known platelet disorder.

Aspirin and clopidogrel response variability: review of the published literature. Genetic determinants of response to clopidogrel and cardiovascular events. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. Prasugrel versus clopidogrel in patients with acute coronary syndromes. Inhibition of platelet aggregation with prasugrel and clopidogrel: an integrated analysis in 846 subjects.

	Guest	#1 \| Posted: Tuesday, September 6, 2011
Switching directly to prasugrel from clopidogrel results in plavix drug eluting stents inhibition of platelet aggregation in aspirintreated subjects. What is the cutoff value for identifying patients who are low responders to clopidogrel plavix type of drug? Subject with known active pathological bleeding or heightened risk of bleeding including but not limited to: gastrointestinal bleeding within 6 months, recent surgery or trauma. Inability of subject to provide informed consent. How to optimise clopidogrel therapy? Plavix drug eluting stents the lowresponse incidence by aggregometryguided therapy modification. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. In subjects with high residual levels of plavix drug eluting stents reactivity after receiving either a maintenance or loading dose of either clopidogrel or prasugrel, a cross over of thienopyridine treatment to the alternate medication will occur. Subject must be taking aspirin or enteric coated aspirin 81 mg325 mg daily. Willing to participate and sign an informed consent. Subject weight is 60 kg or plavix drug eluting stents. Subject with a known platelet disorder. Aspirin and clopidogrel response variability: review of the published literature. Genetic determinants of response to clopidogrel and cardiovascular events. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. Prasugrel versus clopidogrel in patients with acute coronary syndromes. Inhibition of platelet aggregation with prasugrel and clopidogrel: an integrated analysis in 846 subjects.